Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are welcome.
You are most correct about the perpetual BIG IF now at about 6-8 years and counting. BUT all will be forgiven if large shipments start this month and show up in the financials.
Thanks GC. Not sure what to make of the arrangement (whether it's good deal for VDRM). Sounds like Biogenx will fund the costs of production, distribution and marketing of VitaStem. Then split the gross profit from sales 50/50 with VDRM. Sounds like Biogenx will be taking all of the risk. We'll see. At this point we are at the Doc's mercy. Over simplifying here, but if they produce and the stock price goes up, I'll be happy. As we have seen, its a big IF. Still holding.
Fast track wanted verification nothing 2 do with U
Grandmasim The post was NOT directed to you.
If we start seeing 10 & 20 mill then worry.
People in the know would be selling off.
BIG FISH MAN I think you will be proven wrong
TO GET OUT OF AN EXPERT MARKET IS PURE NIGHT MARE.MEDH IS BEEN TRYING FOR MANY MONTHS.BACK AND FORTH WITH OTC.SEND THIS AND SEND THAT.AND NOTHING HAPPENS.WHEN VDRM GOES TO EXPERT MARKET.IT WILL TAKE MANY YEARS TO GET OUT OF IT.=DEAD MONEY FOR A VERY LONG TIME.
YUP.AFTER I SAW THE RECENT E-MAIL FROM IR HERE.EVEN THOUGH I SEND IT MAY TIMES,IT IS GOING EXPERT MARKET.
So I guess you called off loading your boat with .09s .. for the big flip $$$$ darn and I have some to sell 😀
I hope yours don't turn brown like mine did. Not good. I have complained to them and never heard anything back.
Fast track see below.>>>>>>>>>>>>>>>>>>>>>>>>>
Paid with
GM Card
(MasterCard Credit Card
You'll see "PAYPAL *VIADERMA" on your card statement.
$99.95
on March 4, 2024
Ship to
Transaction ID
7EB64999V41615933
Seller info
Biogenx.inc
info@viaderma.com
Invoice ID
#365
Purchase details
Vitastem Ultra 55ML Spray
$99.95
Total
$99.95
See my reply to previous mention of Biogenx #72137
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173972746
Yeah....definitely not a Parent Co.....
Really? No sh** why do you keep asking about Biogenix then? You said you've done a ton of DD and you were clueless......SMFH 🤡
Slops, not doubting that you were told that (Parent Co.), but being a Parent company suggests that Biogenx now owns a controlling interest in VDRM. I think that if another company bought a controlling interest in VDRM, it would have been announced that way and we may have even had to vote on that; being that such a transaction would be a fundamental corporate transaction usually requiring the vote of the shareholders.
If I had to guess, BIOGENX is probably owned by Adams and the Doc as a privately held entity. There's probably an agreement between VDRM and Biogenx whereby VDRM has engaged Biogenx to distribute the product; naturally for a hefty percentage of the gross revenues that solely benefits the Doc and Adam.
GM All of that info is 8 - 10 yrs. old. HISTORY
PEOPLE STARTED BAILING.LOOKS LIKE THE END IS NEAR.FOR THIS POS STOCK.
Mistral
Re: None
Saturday, 03/04/2017 11:16:50 PM
On January 11, 2017, Dr. Otiko issued a news release announcing he signed two pharmaceutical companies, BIOGENX and Chemo-Pharma, Ltd. This was just four weeks after BIOGENX was formed in Nevada. This means they have no business history in pharmaceuticals and distribution of same.
BIOGENX, was registered December 14, 2016 by its President, Secretary, Treasurer and Sole Director:
Garrett Royce Adams
19772 Trident Lane
Huntington Beach, CA 92646
Nevada Registration for BIOGENX
BIOGENX began posting on a Facebook Account December 30, 2016.
BIOGENX FACEBOOK PAGE
A Twitter Account was also created in December 2016.
BIOGENX Twitter Account
On January 5, 2017, Dr. Otiko and Garrett Adams registered the trademark for BIOGENX for "Product Development" and Distribution services, namely, delivery of VitaStem and similar antibiotic creams and ointments.
Garrett Adams' Trademark Activity is in the link below. Most were abandoned, one has opposition pending.
https://trademarks.justia.com/owners/adams-garrett-3156889
Garrett Adams LinkedIn
On LI, Garrett Adams lists himself as President of Neurogenx NerveCenter in Newport Beach as of September 2016. His education is in law, not medicine.
In 2010, the Department of Justice barred Mr. Adams from preparing tax returns for customers and from promoting tax fraud schemes.
Federal Court Bars Multi-Million Dollar Tax Fraud Scheme Operating in Southern California
Interestingly, in 2014, Adams formed Intuit Consulting Group, LLC in California (#201426810271) using the same Huntington Beach address
sunrise73 I put it on your credit card do U mind?
Fort Lauderdale, FL Fulfillment Center 855-222-4601
News is spreading that you bought another bottle. Very bold. Wow.
BIG FISH No one bailing what's up with that?
think IR may be shipping the product local
I did lot's of D&D & don't know any more.
Why is it shipped out of E coast Florida?
I called vdrm they said it's a parent Co.
Fastrack it was Biogenx Inc.A parent Co.
That's great, confirmation that the product exists and is being sold. Slops if I may ask, who was the payee on the order?
Received VitaStem order today Ultra Clear Formula. There is no info in the box like what it can treat.
Product was shipped from Viaderma Distrubution
291 NW 22nd Ave Unit 100 Fort Lauderdale FL 33311. I am glad to see it's ultra clear formula Not like the last.
Delivery time only 3 days.
PEOPLE ARE BAILING LIKE I SAID EXPERT MARKET NEXT STOP.OTIKO GOT US.LIKE I PREDICTED.SCAMBAG.
In my opinion, you really mean PR (Public Relations), i.e., Intent Sciences, if the contract is still in place, and, even then, they would need information from management to communicate. On the other hand, IR is quite limited legally in what he can communicate. IR, in my opinion, is still very lax by not answering emails for long periods of time, with, at least "There is no additional information to communicate at this time." or the like.
His previous response was on Jan 31st. He stated "the next 2 Q's are close to being completed." I waited to begin following up until 2/20/24. Sadly, I have found that one must almost be a total nuisance to get a response, thus, I email every couple of business days until I get a response. The excerpt posted was from response received today.
how long ago did you send an email to IR? I can't seem to get a response in a timely manner if at all. funny how IR says he is frustrated at the accountant all well IR is not doing their part with PRs to update its shareholders either.
No, just no interest. Waiting on the Doc to produce....zzzzzzzzzzzzz
Is there a trading halt for VDRM? There are no trades today for the first two hours. Do trading halts get posted somewhere?
Excerpt from today's response, finally, from IR on Overdue Reports:
"My hope is that everything will be caught up to date by the end of this month, which is when the annual is due. I know the accountant is working on it because she's reached out to me about a couple of things. It's very frustrating and I appreciate your patience. I'm right there with you in the frustration department."
I see.....Doc 😉
Great movie by the way 👍
Got that from the movie tombstone.
Followers
|
615
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
74011
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |